Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Dynamic Reprogramming of Immune-Related Signaling During Progression to Enzalutamide Resistance in Prostate Cancer

Cancers(2025)10.3390/cancers17193187Source: DataRank Database

Dynamic Reprogramming of Immune-Related Signaling During Progression to Enzalutamide Resistance in Prostate Cancer is a research paper published in Cancers (2025). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 1.40)OA: goldTopics (13)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Huan Qu ORCID,Joy C. Yang ORCID,Wei Fan ORCID,Junwei Zhao ORCID,Menghuan Tang

Live enrichment

PubMed:41097714 PMC:PMC12524111 OpenAlex:https://openalex.org/W4414656879

National Institutes of Health/National Cancer Institute

Grant: 1R37CA249108-26

National Institutes of Health/National Cancer Institute

Grant: 1R01CA251253-21

National Institutes of Health/National Cancer Institute

Grant: 1R21CA277171-25

Department of Defense

Grant: HT9425-23-1-0144

Department of Defense

Grant: HT9425-23-1-0325

Department of Defense

Grant: HT9425-23-1-0324

UC Davis Comprehensive Cancer Center Support Grant (CCSG) awarded by the National Cancer Institute

Grant: NCI P30CA093373

NCI NIH HHS

Grant: P30 CA093373

FWCI

1.40

Citation Percentile

0.8%

Citation Trend

2026

goldLicense: cc-by

journalhttps://doi.org/10.3390/cancers17193187

publisherhttps://doi.org/10.3390/cancers17193187

publisherhttps://www.mdpi.com/2072-6694/17/19/3187/pdf

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41097714

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/12524111

Fields of Study

Prostate Cancer Treatment and ResearchCancer, Stress, Anesthesia, and Immune ResponseGlioma Diagnosis and Treatment

Keywords

EnzalutamideProstate cancerReprogrammingImmune systemLineage (genetic)Signal transductionJak/statLineage PlasticityEnzalutamide ResistanceImmune-Related Signaling

Dynamic Reprogramming of Immune-Related Signaling During Progression to Enzalutamide Resistance in Prostate Cancer

FAIR Checklist

Authors (14)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)